Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [18F]SiTATE

Medientyp: E-Artikel

Titel: Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [18F]SiTATE

Beteiligte: Eschbach, Ralf Stefan [Verfasser:in]; Hofmann, Markus [Verfasser:in]; Späth, Lukas [Verfasser:in]; Sheikh, Gabriel T. [Verfasser:in]; Delker, Astrid [Verfasser:in]; Lindner, Simon [Verfasser:in]; Jurkschat, Klaus [Verfasser:in]; Wängler, Carmen [Verfasser:in]; Wängler, Björn [Verfasser:in]; Schirrmacher, Ralf [Verfasser:in]; Tiling, Reinhold [Verfasser:in]; Brendel, Matthias [Verfasser:in]; Wenter, Vera [Verfasser:in]; Dekorsy, Franziska J. [Verfasser:in]; Zacherl, Mathias J. [Verfasser:in]; Todica, Andrei [Verfasser:in]; Ilhan, Harun [Verfasser:in]; Grawe, Freba [Verfasser:in]; Cyran, Clemens C. [Verfasser:in]; Unterrainer, Marcus [Verfasser:in]; Rübenthaler, Johannes [Verfasser:in]; Knösel, Thomas [Verfasser:in]; Paul, Tanja [Verfasser:in]; Boeck, Stefan [Verfasser:in]; Westphalen, Christoph Benedikt [Verfasser:in]; Spitzweg, Christine [Verfasser:in]; Auernhammer, Christoph J. [Verfasser:in]; Bartenstein, Peter [Verfasser:in]; Unterrainer, Lena M. [Verfasser:in]; Beyer, Leonie [Verfasser:in]

Erschienen: 30 January 2023

Sprache: Englisch

DOI: 10.3389/fonc.2023.992316

Identifikator:

Schlagwörter: Molecular Imaging ; NET ; PET/CT ; Somatostatin analogues ; somatostatin receptor

Entstehung:

Anmerkungen: Im Titel ist die Zahl 18 hochgestellt

Beschreibung: Purpose: Somatostatin analogues (SSA) are frequently used in the treatment of neuroendocrine tumours. Recently, [18F]SiTATE entered the field of somatostatin receptor (SSR) positron emission tomography (PET)/computed tomography (CT) imaging. The purpose of this study was to compare the SSR-expression of differentiated gastroentero-pancreatic neuroendocrine tumours (GEP-NET) measured by [18F]SiTATE-PET/CT in patients with and without previous treatment with long-acting SSAs to evaluate if SSA treatment needs to be paused prior to [18F]SiTATE-PET/CT. Methods: 77 patients were examined with standardised [18F]SiTATE-PET/CT within clinical routine: 40 patients with long-acting SSAs up to 28 days prior to PET/CT examination and 37 patients without pre-treatment with SSAs. Maximum and mean standardized uptake values (SUVmax and SUVmean) of tumours and metastases (liver, lymphnode, mesenteric/peritoneal and bones) as well as representative background tissues (liver, spleen, adrenal gland, blood pool, small intestine, lung, bone) were measured, SUV ratios (SUVR) were calculated between tumours/metastases and liver, likewise between tumours/metastases and corresponding specific background, and compared between the two groups. Results: SUVmean of liver (5.4 ± 1.5 vs. 6.8 ± 1.8) and spleen (17.5 ± 6.8 vs. 36.7 ± 10.3) were significantly lower (p < 0.001) and SUVmean of blood pool (1.7 ± 0.6 vs. 1.3 ± 0.3) was significantly higher (p < 0.001) in patients with SSA pre-treatment compared to patients without. No significant differences between tumour-to-liver and specific tumour-to-background SUVRs were observed between both groups (all p > 0.05). Conclusion: In patients previously treated with SSAs, a significantly lower SSR expression ([18F]SiTATE uptake) in normal liver and spleen tissue was observed, as previously reported for 68Ga-labelled SSAs, without significant reduction of tumour-to-background contrast. Therefore, there is no evidence that SSA treatment needs to be paused prior to [18F]SiTATE-PET/CT.

Zugangsstatus: Freier Zugang

Nur in Feld suchen:

Zuletzt gesuchte Begriffe: